Atsuhito Takeda

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial

Hiroyuki Suzuki, Masaru Terai, Shigeto Fuse et al. · The Lancet · 2019 · 208 citations

Medicine, Cardiology, Immunology +11

Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events

Masaru Miura, Tohru Kobayashi, Tetsuji Kaneko et al. · JAMA Pediatrics · 2018 · 148 citations · Full text

Medicine, Cardiology, Internal Medicine +17

Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter

Eriko Kawamura, Minako Maruyama, Jiro Abe et al. · Molecular Therapy — Nucleic Acids · 2020 · 82 citations · Full text

Life Sciences, Biotechnology, Molecular Biology +13

Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium

Jiro Abe, Yuma Yamada, Atsuhito Takeda et al. · Journal of Controlled Release · 2017 · 69 citations

Life Sciences, Cardiology, Cell Biology +17

Enhanced Aortic Pressure Wave Reflection in Patients After Repair of Aortic Coarctation

Tomoaki Murakami, Atsuhito Takeda · The Annals of Thoracic Surgery · 2005 · 52 citations · Full text

Medicine, Cardiology, Surgery +14